JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) INHIBITS T CELL PROLIFERATION VIA THE ECTONUCLEOTIDASE CD39 AND THE PURINERGIC NETWORK

EHA Library, Jovana Rajak, 385450

FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY

EHA Library, Marek Mraz, 387842

NATURAL CLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH BIMODAL CD49D EXPRESSION REVEALS CD49D PLASTICITY

EHA Library, Erika Tissino, 387843

BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL

EHA Library, Sigrid Skånland, 387844

VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

EHA Library, Othman Al-Sawaf, 387845

GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY

EHA Library, Jennifer Brown, 387846

EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

EHA Library, Anna Maria Frustaci, 387847

TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL

EHA Library, Arnon Kater, 387848

OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.

EHA Library, Thomas Chatzikonstantinou, 387849

TIMING AND CLONAL TRAJECTORY TO CHRONIC MYELOID LEUKAEMIA DRIVEN BY THE PHILADELPHIA CHROMOSOME

EHA Library, Aleksandra Kamizela, 387850

COMBINATION OF LARGE SPLEEN AND LOW IN VIVO KINASE INHIBITION IS AN EARLY PREDICTOR OF INFERIOR MOLECULAR RESPONSE AND POOR OUTCOMES IN CHRONIC MYELOID LEUKAEMIA

EHA Library, Tim P. Hughes, 387851

COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL

EHA Library, Nikola Čuřík, 387852

MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS

EHA Library, Ernesto José Cuenca Zamora, 387853

IDENTIFICATION OF NOVEL FACTORS CONTROLLING NON GENETIC CELL PLASTICITY IN CHRONIC MYELOID LEUKEMIA

EHA Library, Guido Baselli, 387854

PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL

EHA Library, Markus Pfirrmann, 387855

FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.

EHA Library, Thomas Ernst, 387856

NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.

EHA Library, Andreas Hochhaus, 387857

EFFICACY OF LOW-DOSE TYROSINE KINASE INHIBITOR THERAPY AFTER ACHIEVING MAJOR MOLECULAR RESPONSE IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA

EHA Library, Qian Jiang, 387858

HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY

EHA Library, Fabio Efficace, 387859

GATA2B HAPLOINSUFFICIENCY CAUSES ABERRANT TRANSCRIPTIONAL REGULATORY SIGNATURES IN HSPCS RESULTING IN MYELOID AND ERYTHROID DYSPLASIA IN ZEBRAFISH

EHA Library, wei zhang, 387860

UBA1 NON-M41 VARIANTS ARE MORE AGGRESSIVE THAN UBA1 M41 VARIANTS IN THEIR HEMATOLOGICAL MANIFESTATIONS.

EHA Library, Maki Sakuma, 387861

LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES

EHA Library, Nicolas Chapuis, 387862

POLYSOME INTERACTOME IN RPS14-DEFICIENT CELLS REVEALS THE INVOLVEMENT OF THE MRNA DECAY MACHINERY IN TRANSLATION SELECTIVITY.

EHA Library, ismael boussaid, 387863

DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

EHA Library, Valeria Santini, 387864

CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

EHA Library, Uwe Platzbecker, 387865

KER-050 TREATMENT IMPROVED MARKERS OF ERYTHROPOIETIC ACTIVITY AND HEMATOPOIESIS OVER SIX MONTHS WHICH RESULTED IN HEMATOLOGICAL RESPONSES ACROSS A BROAD, LOWER-RISK MDS POPULATION

EHA Library, Aristoteles Giagounidis, 387866

MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY

EHA Library, Nicolas Chapuis, 387869

MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)

EHA Library, Rami S. Komrokji, 387870

HIGHER MDMX EXPRESSION WAS ASSOCIATED WITH HYPOMETHYLATING AGENT RESISTANCE AND WORSE SURVIVAL IN MYELODYSPLASTIC SYNDROME PATIENTS, INFERRING IT A POTENTIAL THERAPEUTIC TARGET

EHA Library, Yu-Hung Wang, 387871

PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Alex Bataller, 387872

RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY

EHA Library, Elena Crisà, 387873

MYELOID NGS ANALYSES OF PAIRED SAMPLES FROM BONE MARROW AND PERIPHERAL BLOOD YIELD CONCORDANT RESULTS: A PROSPECTIVE COHORT ANALYSIS OF THE AGMT STUDY GROUP

EHA Library, Lisa Pleyer, 387874

SINGLE-CELL ANALYSIS REVEALS SOMATIC TP53 MUTATIONS EMERGE IN EARLY PROGENITOR CELLS BUT BECOME ENRICHED IN THE ERYTHROID LINEAGE IN ERCC6L2 DISEASE

EHA Library, Laura Langohr, 387875

FUNCTIONAL AND ANTIGEN-SPECIFIC CHARACTERIZATION OF IMMUNE CELLS AT THE SINGLE-CELL LEVEL REVEALS CONVERGENCE OF ADAPTIVE AND INNATE IMMUNITY IN IMMUNE APLASTIC ANEMIA

EHA Library, Jani Huuhtanen, 387876

JAK INHIBITION AND COMBINATION THERAPY IN THE TREATMENT OF MURINE BONE MARROW FAILURE

EHA Library, Xingmin Feng, 387877

A NEW HEREDITARY SYNDROME WITH SEVERE NEUTROPENIA AND NEUROLOGICAL INVOLVEMENT CAUSED BY THE AUTOSOMAL RECESSIVE COPZ1 MUTATION

EHA Library, Natalia Borbaran Bravo, 387878

HNRNPK OVEREXPRESSION DRIVES NUCLEOLAR ABERRANCIES CAUSING RIBOSOMPATHIES

EHA Library, Pedro Aguilar Garrido, 387879

THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS

EHA Library, Alexander Röth, 387881

ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA

EHA Library, Antonio Maria Risitano, 387882

PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

EHA Library, Austin Kulasekararaj, 387883

SAFETY AND OUTCOMES FOLLOWING IMMUNOSUPPRESSIVE THERAPY WITH ATG/CYCLOSPORIN +/- ELTROMBOPAG FOR OLDER PATIENTS WITH SEVERE APLASTIC ANEMIA

EHA Library, Ashvind Prabahran, 387884

TARGETING DNA2 OVERCOMES METABOLIC REPROGRAMMING IN 1Q21 MULTIPLE MYELOMA

EHA Library, Natthakan Thongon, 387885

ACQUIRED RESISTANCE TO BISPECIFIC ANTIBODIES BY GENETIC OR EPIGENETIC INACTIVATION OF THE TARGET IN MULTIPLE MYELOMA

EHA Library, Eric Letouzé, 387886

IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL OUTCOME IN ELDERLY MULTIPLE MYELOMA PATIENTS

EHA Library, Wassilis Bruins, 387887

CAR-T CELLS SHAPE THE IMMUNOLOGICAL POTENTIAL OF THE TUMOR MICROENVIRONMENT

EHA Library, Julia Frede, 387888

PROTEOGENOMIC LANDSCAPE OF MULTIPLE MYELOMA

EHA Library, Evelyn Ramberger, 387889

BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY

EHA Library, Susan Bal, 387893

TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY

EHA Library, Fritz Offner, 387894

IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS

EHA Library, Krina Patel, 387895

ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3

EHA Library, Mohamad Mohty, 387896

LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Hans C. Lee, 387897

EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

EHA Library, Efstathios Kastritis, 387898

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL

EHA Library, Petra Langerbeins, 387900

FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)

EHA Library, Arnon Kater, 387901

QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL

EHA Library, Luciano Costa, 387903

SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, COMBINED WITH ANTI-PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: 18-MONTH RESULTS OF A PHASE 2 STUDY

EHA Library, Jason Valent, 387904

INHIBITING THE ALARMIN-DRIVEN HEMATOPOIESIS-STROMAL CELLS CROSSTALK IN PRIMARY MYELOFIBROSIS AMELIORATES BONE MARROW FIBROSIS

EHA Library, Hélène Gleitz, 387905

ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT

EHA Library, Mark Hartmann, 387906

NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL

EHA Library, Xiaoli Wang, 387907

RELEVANCE OF DORMANT CANCER STEM CELLS IN DISEASE PROPAGATION AND THERAPY RESISTANCEIN JAK2V617F-DRIVEN MPN.

EHA Library, Ian Ghezzi, 387908

TARGETING THE SRC HOMOLOGY 2 DOMAIN-CONTAINING PHOSPHATASE SHP2 ENHANCES THE THERAPEUTIC EFFICACY OF JAK INHIBITION IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Sarah Jungius, 387909

AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX

EHA Library, John Mascarenhas, 387910

EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-1 RISK MYELOFIBROSIS: UPDATED RESULTS AND GENOMIC CHARACTERISTICS

EHA Library, Harry Gill, 387911

A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS

EHA Library, Yi Zhang, 387912

BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

EHA Library, Haifa Kathrin Al-Ali, 387913

DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

EHA Library, Pankit Vachhani, 387914

CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY

EHA Library, Jingwei Yu, 387916

POST-TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION

EHA Library, Fabio Guolo, 387917

CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS

EHA Library, Bastian von Tresckow, 387918

PREDICTING THROMBOTIC RISK IN PATIENTS WITH HODGKIN LYMPHOMA: A MULTICENTRIC STUDY OF THROLY AND KHORANA RISK SCORES

EHA Library, Ilaria Del Giudice, 387919

REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT

EHA Library, Nausheen Ahmed, 387920

LONG-TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)

EHA Library, Marco Ladetto, 387921

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

EHA Library, Anna Sureda, 387922

REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Caron Jacobson, 387923

ALLOGENEIC STEM CELL TRANSPLANTATION FOR NK/T-CELL LYMPHOMA IN THE ERA OF ASPARAGINASE-BASED CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY

EHA Library, Philipp Berning, 387925

EFFICACY OF ANTI-PD1 THERAPY  IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA

EHA Library, Amira Marouf, 387926

INITIAL SAFETY DATA FROM THE PHASE 3 POLAR BEAR TRIAL IN ELDERLY OR FRAIL PATIENTS WITH DIFFUSE LARGE CELL LYMPHOMA, COMPARING R-POLA-MINI-CHP AND R-MINI-CHOP

EHA Library, Sirpa Leppä, 387927

POSITRON EMISSION TOMOGRAPHY EVALUATION IN A LARGE GROUP OF PATIENTS AFFECTED BY RELAPSED/REFRACTORY B-CELL LYMPHOMAS TREATED WITH ANTI-19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS THERAPY (CART SIE).

EHA Library, Anna Dodero, 387928

PROPHYLACTIC EFFICACY OF INTRATHECAL VERSUS INTRAVENOUS METHOTREXATE FOR CNS RELAPSE IN HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA : A PHASE III RANDOMIZED, CONTROLLED STUDY

EHA Library, Seung-Ah Yahng, 387929

CD22 CAR T CELL THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH LARGE B CELL LYMPHOMA WHO HAVE RELAPSED AFTER CD19 CAR T CELL THERAPY.

EHA Library, Matthew J. Frank, 387930

PRIMARY MEDIASTINAL B-CELL LYMPHOMA HAVE A SUPERIOR OUTCOME COMPARED TO DIFFUSE LARGE-B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL IN THE CART-SIE REAL LIFE ITALIAN STUDY

EHA Library, Annalisa Chiappella, 387931

EFFICACY AND TOXICITY OF CAR-T CELLS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS, A NEW REFERENCE: THE FRENCH EXPERIENCE OF THE NATIONAL LOC NETWORK

EHA Library, Sylvain Choquet, 387932

AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY

EHA Library, Roch Houot, 387933

UPDATED CLINICAL RESULTS OF FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA

EHA Library, Yi Zhang, 387934

GENERATION AND APPLICATION OF A LIVING T-CELL LYMPHOMA PATIENT-DERIVED TUMOR XENOGRAFT BIOREPOSITORY

EHA Library, Luca Vincenzo Cappelli, 387935

HIGH-BREADTH SEQUENCING OF CIRCULATING TUMOR DNA IDENTIFIES NOVEL CLASSIFICATION OF HODGKIN LYMPHOMA

EHA Library, Julia Mattlener, 387936

THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T-CELL LYMPHOMA

EHA Library, Yasuhito Suehara, 387937

CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY

EHA Library, Ivan SLOMA, 387938

SOX11 DRIVES B1A LINEAGE COMMITMENT AND B1A/MCL-LIKE LYMPHOMA FORMATION IN MICE

EHA Library, Tim Pieters, 387939

TARGETING PRMT1 ALLEVIATES CHRONIC GRAFT-VERSUS-HOST DISEASE BY REDUCING T AND B PATHOGENICITY

EHA Library, Xiaoyan Zhao, 387940

ITACONATE INHIBITS TH1 DIFFERENTIATION AND ACUTE GRAFT-VERSUS-HOST DISEASE VIA NRF2

EHA Library, Yaoyao Shen, 387941

IPSC DISEASE MODELS TO STUDY AND TREAT DIAMOND-BLACKFAN ANEMIA SYNDROME (DBAS)

EHA Library, Marije Bartels, 387977

CEREBRAL HEMODYNAMICS AND OXYGEN METABOLISM IN PATIENTS WITH MILD AND SEVERE SICKLE CELL DISEASE AND THALASSEMIA

EHA Library, Liza Afzali-Hashemi, 387978

EFFECT OF VOXELOTOR ON CEREBRAL PERFUSION AND CEREBRAL OXYGEN METABOLISM IN ADULT PATIENTS WITH SICKLE CELL DISEASE; THE COVERAGE STUDY

EHA Library, Kadère Konté, 387979

INDIVIDUALS WITH HFE C282Y HOMOZYGOSITY AND DIABETES HAVE ALMOST TWO-FOLD RISK OF DEATH COMPARED TO NON-CARRIERS WITH DIABETES: A PROSPECTIVE STUDY OF A 132,542-INDIVIDUAL GENERAL POPULATION COHORT

EHA Library, Mathis Mottelson, 387980

TMPRSS6 INHIBITION WITH A MONOCLONAL ANTIBODY IMPROVES RED BLOOD CELL HEALTH AND IRON OVERLOAD IN A MOUSE MODEL OF BETA-THALASSEMIA

EHA Library, Heinrich Lob, 387981

ERYTHROPOIESIS INDUCTION THROUGH BONE MARROW TFR2 DELETION REDUCES BLOOD GLUCOSE LEVELS IN WILD-TYPE AND Β-THALASSEMIC MICE

EHA Library, Antonella Nai, 387982

THE NON-ANTICOAGULANT HEPARINOID COMPOUND, SEVUPARIN, STRONGLY REDUCES HEPCIDIN EXPRESSION IN CELLS, IN MICE AND IN HEALTHY VOLUNTEERS

EHA Library, Michela Asperti, 387983

HEPATOCYTE TOLL-LIKE RECEPTORS MEDIATE THE HEPCIDIN INFLAMMATORY RESPONSE TO PATHOGENS AND PATHOGEN-DERIVED LIGANDS

EHA Library, Oriana Marques, 387984

DISSECTING THE ROLE OF THE IMMUNOPHILIN FKBP12 IN HEPCIDIN REGULATION

EHA Library, Laura Silvestri, 387985